Directori de persones
Alfons Segarra Medrano

Alfons Segarra Medrano

Grau: Doctor/a


asegarra.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/R-9077-2019

Grups

Publicacions

  • Bauer, C; Piani, F; Troost, J; Da Sacco, S; Rojas-Sanchez, G; Davizon-Castillo, P; Perin, L; Daehn, I; Islam, MI; Fetsko, A; Carrera-Muñoz, C; Rovin, B; Zhang, XL; Banks, M; de Lucas-Collantes, C; Ordóñez-Alvarez, FA; Aparicio-López, C; Lanaspa, MA; Andres-Hernando, A; Segarra, A; Martinez, C; Bjornstad, P; Lucia, MS; Schaefer, F; Yilmaz, A; Zurowska, A; Wang, X; Mccown, PJ; Eddy, S; Hartman, J; Mariani, L; Kretzler, M; Zhu, YW; Bouts, AHM; Levtchenko, EN; Dougherty, JA; Smoyer, WE; Kerlin, BA; Kallash, M; Soranno, DE; Cabrera-Sevilla, JE; Gonzalez-Rodriguez, JD; Siegele, BJ; Tsuji, S; Kaneko, K; Sethna, CB; Srivastava, T; Bitzer, M; O'Connor, CL; Dimberg, A; Zhao, SRA; Yu, LP; Thurman, JM; Johnson, RJ; Cara-Fuentes, G

    Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome

    Science Translational Medicine 18 -. .

    [doi:10.1126/scitranslmed.adw2206]

  • Planella-Cornudella, M; Roca-Saladrigues, N; Lopez-Baez, V; Jatem-Escalante, E; Sole-Mir, E; Gomez-Arbones, X; Madrid-Aris, A; Segarra-Medrano, A

    Lymphocytic expression and IL-2 levels in calcineurin inhibitor-resistant nephrotic syndrome due to focal segmental glomerulosclerosis: implications for calcineurin inhibitor response

    Nefrologia 46 -. .

    [doi:10.1016/j.nefro.2025.501402]

  • Rodríguez, JG; Valdivielso, JM; Escalante, EJ; Sans, MB; Carrasco, AG; Salas, JD; Alcalá, AM; Ribas, MP; Roldan, EO; Medrano, AS; Conde, MLM

    Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy

    BMC Nephrology 26 141-141. .

    [doi:10.1186/s12882-025-04049-8]

  • González, J; Jatem, E; del Carpio, J; Castañeda, ZI; Abó, AI; Martín, ML; Segarra, A

    Epidemiological, clinical and prognostic issues in SARS-CoV-2 infection or vaccination-related glomerular disease: Our single-center experience

    Nefrologia 44 582-583. .

    [doi:10.1016/j.nefro.2023.10.006]

  • Gonzalez J; Jatem E; Roig J; Valtierra N; Ostos E; Abo A; Santacana M; Garcia A; Segarra A

    Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 37 2102-2110. .

    [doi:10.1093/ndt/gfac185]

  • Bauer, C; Piani, F; Banks, M; Ordoñez FA; de Lucas-Collantes, C; Oshima, K; Schmidt, EP; Zakharevich, I; Segarra, A; Martinez, C; Roncal-Jimenez, C; Satchell, SC; Bjornstad, P; Lucia, MS; Blaine, J; Thurman, JM; Johnson, RJ; Cara-Fuentes, G

    Minimal Change Disease Is Associated With Endothelial Glycocalyx Degradation and Endothelial Activation.

    Kidney International Reports 7 797-809. .

    [doi:10.1016/j.ekir.2021.11.037]

  • Roca, N; Jatem, E; Abo, A; Santacana, M; Cruz, A; Madrid, A; Fraga, G; Martin, M; Gonzalez, J; Martinez, C; Balius, A; Segarra, A

    CD44-negative parietal-epithelial cell staining in minimal change disease: association with clinical features, response to corticosteroids and kidney outcome.

    Clinical Kidney Journal 15 545-552. .

    [doi:10.1093/ckj/sfab215]

  • Molina, M; Sorolla, C; Samsó, E; Carcaña, M; Martín, ML; Jatem, E; Pitarch, G; Montero, L; Lauzurica, R; Segarra, A

    Quality of Life in Long-Term Renal Transplant Patients: A Controversial Subject

    TRANSPLANTATION PROCEEDINGS 54 91-93. .

    [doi:10.1016/j.transproceed.2021.11.025]

  • Molina, M; Sorolla, C; Samsó, E; Carcaña, M; Martín, ML; Jatem, E; Pitarch, G; Montero, L; Lauzurica, R; Segarra, A

    Cost of Traveling to Follow-up Appointments at Kidney Transplant Clinics

    TRANSPLANTATION PROCEEDINGS 54 94-95. .

    [doi:10.1016/j.transproceed.2021.11.005]

  • Medrano AS; Muijsemberg A; Wimbury D; Martin M; Jatem E; González J; Colás-Campás L; García-Carrasco A; Martínez C; Barratt J

    Relationship between IgA1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in IgA nephropathy.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 37 318-325. .

    [doi:10.1093/ndt/gfaa356]

  • Jatem-Escalante, E; Martín-Conde, ML; Gracia-Lavedan, E; Benítez, ID; Gonzalez, J; Colás, L; Garcia-Carrasco, A; Martínez, C; Segarra-Medrano, A

    Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy

    Clinical Kidney Journal 14 2556-2562. .

    [doi:10.1093/ckj/sfab116]

  • Del Carpio, J; Marco, MP; Martin, ML; Craver, L; Jatem, E; Gonzalez, J; Chang, P; Ibarz, M; Pico, S; Falcon, G; Canales, M; Huertas, E; Romero, I; Nieto, N; Segarra, A

    External validation of the Madrid Acute Kidney Injury Prediction Score

    Clinical Kidney Journal 14 2377-2382. .

    [doi:10.1093/ckj/sfab068]

Projectes

  • Relación entre glicoformas de IgA1 e IgA2, actividad clínica y activación del complemento en la nefropatía IgA